Eye Manifestations Clinical Trial
Official title:
Evaluation of the Effect of Smokeless Tobacco on Anterior Segment Parameters
Verified date | February 2021 |
Source | Kahramanmaras Sutcu Imam University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Observational, comparative, cross-sectional study
Status | Completed |
Enrollment | 107 |
Est. completion date | November 30, 2020 |
Est. primary completion date | July 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 26 Years to 49 Years |
Eligibility | Inclusion Criteria: - A subject who use ST - A subject who was not using ST Exclusion Criteria: - Refractive disorder - Systemic chronic disease (diabetes, hypertension, neurological, etc.) - Ocular trauma - Ocular surgery - Glaucoma - Optic disc abnormalities - Congenital anomaly |
Country | Name | City | State |
---|---|---|---|
Turkey | Abdullah Beyoglu | Kahramanmaras | None Selected |
Lead Sponsor | Collaborator |
---|---|
Kahramanmaras Sutcu Imam University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Central Corneal Thickness (CCT) | Change in Central Corneal Thickness (CCT | Baseline to 60 minutes after intervention | |
Primary | Axial Length (AL) | Change in Axial Length (AL) | Baseline to 60 minutes after intervention | |
Primary | Anterior chamber deep (ACD) | Change in Anterior chamber deep (ACD) | Baseline to 60 minutes after intervention | |
Primary | Lens thickness (LT) | Change in Lens thickness (LT) | Baseline to 60 minutes after intervention | |
Primary | Pupillary diameter (PD) | Change in Pupillary diameter (PD) | Baseline to 60 minutes after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01588041 -
Intraoperative OCT Guidance of Intraocular Surgery
|
||
Recruiting |
NCT05863689 -
Microvascular Ocular Changes of Systemic Lupus Erythematous
|
||
Completed |
NCT06235346 -
Ocular Effects of Synthetic Cannabinoids
|
||
Completed |
NCT04831047 -
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
|
Phase 4 | |
Recruiting |
NCT02912780 -
Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
|
N/A | |
Completed |
NCT04021225 -
Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
|
N/A | |
Recruiting |
NCT00345280 -
Ocular Surface Changes in Patients With Cystic Fibrosis
|
Phase 1 |